ライフサイエンスコーパス: aztreonam

1 or, cefadroxil, cefuroxime, ceftriaxone, and aztreonam.

2 1.2% and an absence of cross-reactivity with aztreonam.

3 dime, cefotaxime, cefepime, cefpodoxime, and aztreonam.

4 rolyze a third-generation lactam antibiotic, aztreonam.

5 ance to extended-spectrum cephalosporins and aztreonam.

6 ance to extended-spectrum cephalosporins and aztreonam.

7 ance to expanded-spectrum cephalosporins and aztreonam.

8 s, particularly in cell filaments induced by aztreonam.

9 atalytic efficiency for both ceftazidime and aztreonam.

10 cephalosporin ceftazidime and the monobactam aztreonam.

11 be treated with cefuroxime, ceftriaxone, and aztreonam.

12 ce) rates were 47 and 27%, respectively, for aztreonam; 59 and 14%, respectively, for cefepime; 44 an

13 w breakpoints and standard concentrations of aztreonam (78), ceftazidime (79), ceftriaxone (83), or c

14 ent detected in parentheses): DD method with aztreonam (95), ceftazidime (79), ceftriaxone (88), or c

15 xone, cefotaxime, ceftazidime, cefepime, and aztreonam agar dilution MIC determination; ESBL screenin

16 2%) for cefepime (VITEK 2 and VITEK) and for aztreonam (all three systems), leading to consistent tre

17 ort ESBL-producing organisms as resistant to aztreonam and all cephalosporins (with the exception of

18 rthermore, we discovered that the monobactam aztreonam and BAL29880, a new beta-lactamase inhibitor o

19 These data indicate the tolerability of both aztreonam and carbapenems in penicillin-allergic subject

20 lts were challenged with escalating doses of aztreonam and carbapenems.

21 displayed negative skin test results to both aztreonam and carbapenems; 211 accepted challenges and t

22 penicillin reagent underwent skin tests with aztreonam and carbapenems; subjects with negative result

23 The incidence of aztreonam and cephalosporin susceptibility, determined u

24 MICs for aztreonam and piperacillin were higher, with MICs for so

25 ess cross-reactivity with cephalosporins and aztreonam and the tolerability of such alternative beta-

26 is gene, which resulted in susceptibility to aztreonam and third- and fourth-generation cephalosporin

27 test results to cefuroxime, ceftriaxone, and aztreonam and tolerated challenges.

28 iving prophylaxis with ampicillin-sulbactam, aztreonam and vancomycin, or tigecycline (P = 0.61).

29 Our analysis showed that results for aztreonam and/or >/=1 cephalosporin were reported as sus

30 four antibiotics (tobramycin, ciprofloxacin, aztreonam, and imipenem), indicating that this has poten

31 istance to extended-spectrum cephalosporins, aztreonam, and penicillin.

32 of PBP3 with three beta-lactams (cephalexin, aztreonam, and piperacillin) in growing cells.

33 conjugates with benzyl penicillin, imipenem, aztreonam, and the siderophore-conjugated monocarbam MC-

34 nical efficacy of ceftazidime/avibactam plus aztreonam as combination therapy for S. maltophilia infe

35 ith the extended-spectrum cephalosporins and aztreonam as resistant as suggested by current National

36 ticles accumulated in cells increases as the aztreonam (AZT) concentration increases and as incubatio

37 -lactam antibiotics, namely, cephalothin and aztreonam, belonging to two different subfamilies.

38 nhibit (e.g. clavulanic acid) or evade (e.g. aztreonam) beta-lactamases have been developed.

39 Aztreonam, cefazolin, cefepime, and, to a lesser extent,

40 mipenem) and others toward false resistance (aztreonam, cefepime, and ceftazidime).

41 0.5%) using the CLSI breakpoints (2 each for aztreonam, cefepime, and ceftriaxone, and 1 for cefazoli

42 stems when five-broad spectrum beta-lactams, aztreonam, cefepime, ceftazidime, imipenem, and piperaci

43 diffusion methodology for susceptibility to aztreonam, cefotaxime, ceftazidime, and cefoxitin.

44 Ceftazidime and aztreonam disks were equivalent in differentiating ESBL

45 per readings for ciprofloxacin, norfloxacin, aztreonam, erythromycin, clindamycin, and trimethoprim-s

46 ts (ceftriaxone for CABP and vancomycin plus aztreonam for ABSSSIs) at both a standard test of cure a

47 We aimed to assess safety and efficacy of aztreonam for inhalation solution (AZLI) in patients wit

48 owing a 28-day, open-label, run-in course of aztreonam for inhalation solution (AZLI).

49 The well-known affinity of the monobactam aztreonam for P. aeruginosa PBP3 is due to a distinct hy

50 terpretative criteria for cephalosporins and aztreonam for testing Enterobacteriaceae.

51 the beta-lactam antibiotics (median values: aztreonam, >128 microg/ml versus 4 microg/ml; ceftazidim

52 Mutants selected for aztreonam hydrolysis exhibited a Gly for Ala substitutio

53 th the G238S:E240K substitutions to increase aztreonam hydrolysis.

54 to cefotaxime, cefuroxime, ceftazadime, and aztreonam, i.e., the "extended-spectrum" phenotype.

55 erococcosel broth (containing vancomycin and aztreonam) identified 88% and may be preferred over othe

56 y found a cross-reactivity rate of 6.2% with aztreonam in 16 such subjects.

57 ance to extended-spectrum cephalosporins and aztreonam in addition to cephamycins, such as cefoxitin.

58 penicillins and cefuroxime, ceftriaxone, and aztreonam in all subjects with T cell-mediated hypersens

59 the possibility of using cephalosporins and aztreonam in subjects with documented delayed hypersensi

60 esistant mutants hyperproduce L1, but retain aztreonam/inhibitor susceptibility because aztreonam is

61 Because aztreonam inhibits AmpCs, a study was designed to compar

62 n aztreonam/inhibitor susceptibility because aztreonam is not an L1 substrate.

63 r S. maltophilia infections and confirm that aztreonam-like beta-lactams plus nonclassical beta-lacta

64 and Acinetobacter baumannii by BOCILLIN FL, aztreonam, meropenem, and ceftazidime.

65 rains producing ESBLs, while ceftriaxone and aztreonam MICs separated low-level K1 from high-level K1

66 plates that contained vancomycin and either aztreonam or ceftazidime were used as the selective medi

67 Acylation of PBP3 with cephalexin, but not aztreonam or piperacillin, appeared to be stimulated by

68 mented CLSI disk test (CLSI plus BA), and an aztreonam plus clavulanate disk test (ATM plus CA).

69 us ceftriaxone, cefepime, ciprofloxacin, and aztreonam promoted increased VRE density to a lesser deg

70 cy for ceftazidime but a 3-fold increase for aztreonam relative to the G238S:E240K double mutant.

71 to detect extended-spectrum cephalosporin or aztreonam resistance in any of the ESBL- or AmpC-produci

72 Three different mutations contribute to aztreonam resistance.

73 (94.3%), for ceftaroline and vancomycin plus aztreonam, respectively, and did not differ from those a

74 activated by the beta-lactams mecillinam and aztreonam, respectively, several mutants did not lyse bu

75 tion of extended-spectrum cephalosporins and aztreonam results from the susceptible to the resistant

76 obacter cloacae versus ampicillin-sulbactam, aztreonam, ticarcillin, and ticarcillin-clavulanate and

77 hose who especially require cephalosporin or aztreonam treatment, however, we recommend pretreatment

78 resistant to carbapenems but susceptible to aztreonam, trimethoprim-sulfamethoxazole, and fluoroquin

79 of ceftazidime, cefotaxime, ceftriaxone, or aztreonam was >or=2 microg/ml or the MIC of cefpodoxime

80 n in differentiating between ceftazidime and aztreonam was further investigated by kinetic analysis o

81 me, cefotaxime, ceftriaxone, ceftazidime, or aztreonam) was associated with bacteremia due to ESBL-pr